<DOC>
	<DOCNO>NCT00400764</DOCNO>
	<brief_summary>This Phase Ib/II , open-label , multicenter trial design evaluate safety , pharmacokinetics , efficacy dulanermin combine rituximab subject follicular , CD20+ , B-cell Non-Hodgkin 's Lymphoma ( NHL ) progress follow response ≥ 6 month duration prior rituximab-containing therapy . The multicenter , international , randomized Phase II part study commence safety available pharmacokinetic data Phase Ib part study evaluate Sponsor provide participate investigator FDA .</brief_summary>
	<brief_title>A Study Dulanermin Combination With Rituximab Subjects With Follicular Other Low Grade , CD20+ , Non-Hodgkin 's Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Signed Informed Consent Form Age ≥ 18 year History histologically confirm CD20+ follicular NHL Grade 1 , 2 , 3a Progression disease follow recent treatment rituximabcontaining therapy result stable disease partial complete response last ≥ 6 month Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 For subject reproductive potential ( male female ) , use reliable mean contraception ( e.g. , contraceptive pill , intrauterine device [ IUD ] , physical barrier throughout trial 1 year follow final exposure study treatment ) . Life expectancy &gt; 3 month Prior radiotherapy measurable , metastatic lesion ( ) use measure response unless lesion show unequivocal progression baseline Radiation therapy peripheral lesion within 14 day prior Day 1 ; Radiation therapy thoracic , abdominal , pelvic field within 28 day prior Day 1 Chemotherapy , hormonal therapy , radiotherapy , immunotherapy within 4 week prior Day 1 Patients receive radioimmunotherapy relapse refractory , follicular NHL eligible study receive therapy least 1 year prior Day 1 , adequate bone marrow function , evidence myelodysplastic syndrome bone marrow aspirate/biopsy Prior treatment dulanermin agonist antibody DR4 DR5 Concurrent systemic corticosteroid therapy Evidence clinically detectable ascites Day 1 Other invasive malignancy within 5 year prior Day 1 History evidence upon physical examination central nervous system ( CNS ) disease within 1 year prior study entry Active infection require parenteral antibiotic Day 1 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study fine needle aspiration within 7 day prior Day 1 Pregnancy lactation Serious nonhealing wound , ulcer , bone fracture Current recent participation another experimental drug study Clinically significant cardiovascular disease Known positive test result HIV , hepatitis B surface antigen ( sAg ) , hepatitis B IgG IgM core antibody , hepatitis C antibody Known sensitivity murine human antibodies History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>NHL</keyword>
	<keyword>Follicular NHL</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Apo2L/TRAIL</keyword>
</DOC>